Enact schedules third-quarter earnings call
Bitget2026/10/08 20:20Enact schedules its third-quarter 2026 earnings release for Nov. 4, 2026, issued after the market close. Conference call set for Nov. 5, 2026 at 8:00 a.m. ET to review results; live webcast via https://ir.enactmi.com/news-and-events/events. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enact Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610081620PRIMZONEFULLFEED9842384) on October 08, 2026, and is solely responsible for the information contained therein.
- Enact schedules its third-quarter 2026 earnings release for Nov. 4, 2026, issued after the market close.
- Conference call set for Nov. 5, 2026 at 8:00 a.m. ET to review results; live webcast via https://ir.enactmi.com/news-and-events/events.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Trump Media & Technology Group plunges over 24%, hitting a new low since listing.
South Korea’s current account surplus in September exceeded 60 billions USD for the first time, with semiconductor exports becoming the main driver
Driven by booming semiconductor exports, South Korea's current account surplus in September surged to a record high.
CoreWeave (CRWV.US) bonds hit a new low as changes in Texas data center policies impact AI cloud trading
CoreWeave (CRWV.US) bonds fell sharply on Wednesday, with some dropping to new lows.
AstraZeneca (AZN.US) reportedly receives a $10 billion acquisition offer! Shares of obesity drug developer Rhythm (RYTM.US) soar in response
According to three people familiar with the matter, AstraZeneca previously proposed to acquire obesity drug developer Rhythm Pharmaceuticals for approximately 10 billion dollars.
Crypto prices
More
